TY - JOUR
T1 - Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities
AU - Sakai, Shunsuke A.
AU - Aoshima, Masato
AU - Sawada, Kentaro
AU - Horasawa, Satoshi
AU - Yoshikawa, Ayumu
AU - Fujisawa, Takao
AU - Kadowaki, Shigenori
AU - Denda, Tadamichi
AU - Matsuhashi, Nobuhisa
AU - Yasui, Hisateru
AU - Goto, Masahiro
AU - Yamazaki, Kentaro
AU - Komatsu, Yoshito
AU - Nakanishi, Ryota
AU - Nakamura, Yoshiaki
AU - Bando, Hideaki
AU - Hamaya, Yamato
AU - Kageyama, Shun Ichiro
AU - Yoshino, Takayuki
AU - Tsuchihara, Katsuya
AU - Yamashita, Riu
N1 - Funding Information:
SK reports honoraria from Eli Lilly, Taiho, Ono, Bristol-Myers Squibb, Chugai, Bayer, Merck Serono, Daiichi Sankyo, Eisai; and research funding from Taiho, Eli Lilly, MSD, Chugai, Nobelpharma, Ono, Daiichi Sankyo, and Yansen.TD reports honoraria from Sawai Pharmaceutical; speakers’ bureau from Sysmex; and research funding from MSD and Ono Pharmaceutical. HY reports honoraria from Taiho Pharmaceutical, Chugai, Bristol-Myers Squibb, Daiichi-Sankyo, Terumo, Eli Lilly Japan, Merck Biopharma, Yakult Honsha, and Bayer Yakuhin; and research funding from MSD, Daiichi-Sankyo, and Ono Pharmaceutical. MG reports honoraria from Yakult Honsha, Taiho Pharmaceutical, Daiichi-Sankyo, Eisai, and Ono Pharmaceutical; and research funding from Chugai, Taiho Pharmaceutical, Nippon Kayaku, Ono Pharmaceutical, and Eli Lilly. YK reports honoraria from Asahi Kasei Pharma, Bayer Yakuhin, Bristol-Myers Squibb., Chugai, Daiichi-Sankyo, Eli Lilly, Kyowa Kirin, Medical Review, Merck Biopharma, Mitsubishi Tanabe Pharma, Moroo, Nipro, Ono Pharmaceutical, Pfizer Japan, Sanofi, Shire Japan, and Taiho Pharmaceutical; and research funding from A2 Healthcare, Asahi Kasei Pharma, Astellas Pharma, Bayer Yakuhin, Daiichi-Sankyo, Sumitomo Dainippon Pharma, Eisai, Mediscience Planning, NanoCarrier, Ono Pharmaceutical, Parexel International, Sanofi-aventis, Shionogi & Co., Ltd., Taiho Pharmaceutical, Yakult Honsha, Incyte, IQVIA, MSD, Nippon Zoki Pharmaceutical, Syneos Health Clinical, and Sysmex. YN reports research grants from Taiho Pharmaceutical, Chugai Pharmaceutical, Guardant Health, Genomedia, Daiichi Sankyo, Seagen, and Roche Diagnostics. HB reports honoraria from Taiho Pharmaceutical, Lilly Japan, Takeda Pharmaceutical, Chugai, Sanofi, and Yakult Honsha: and research funding from AstraZeneca and Sysmex. TY reports honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Merck Biopharma, Bayer Yakuhin, Ono Pharmaceutical, and MSD; and research funding from Ono Pharmaceutical, Sanofi, Daiichi Sankyo, PAREXEL International, Pfizer Japan, Taiho Pharmaceutical, MSD, Amgen, Genomedia, Sysmex, Chugai Pharmaceutical, and Nippon Boehringer Ingelheim KT reports honoraria from SRL Diagnostics, DNA Chip Research, Chugai, Novartis, Takeda, MSD, Sysmex, Nippon Kayaku, Illumina, Fujitsu, Varian Medical Systems, Miyarisan Pharmaceutical, Bristol-Myers Squibb, AstraZeneca, and Novartis. RY reports honoraria from Takeda Pharmaceutical.
Funding Information:
This study was supported by the National Cancer Center Research and Development Fund (grant number 31-A-10). This study was also supported by AMED Seeds A (grant number CPOT, 21-A-33).
Publisher Copyright:
Copyright © 2022 Sakai, Aoshima, Sawada, Horasawa, Yoshikawa, Fujisawa, Kadowaki, Denda, Matsuhashi, Yasui, Goto, Yamazaki, Komatsu, Nakanishi, Nakamura, Bando, Hamaya, Kageyama, Yoshino, Tsuchihara and Yamashita.
PY - 2022/9/14
Y1 - 2022/9/14
N2 - Colorectal cancer (CRC) is one of the most common malignant diseases. Generally, stoma construction is performed following surgery for the resection of the primary tumor in patients with CRC. The association of CRC with the gut microbiota has been widely reported, and the gut microbiota is known to play an important role in the carcinogenesis, progression, and treatment of CRC. In this study, we compared the microbiota of patients with CRC between with and without a stoma using fecal metagenomic sequencing data from SCRUM-Japan MONSTAR-SCREEN, a joint industry-academia cancer research project in Japan. We found that the composition of anaerobes was reduced in patients with a stoma. In particular, the abundance of Alistipes, Akkermansia, Intestinimonas, and methane-producing archaea decreased. We also compared gene function (e.g., KEGG Orthology and KEGG pathway) and found that gene function for methane and short-chain fatty acids (SCFAs) production was underrepresented in patients with a stoma. Furthermore, a stoma decreased Shannon diversity based on taxonomic composition but increased that of the KEGG pathway. These results suggest that the feces of patients with a stoma have a reduced abundance of favorable microbes for cancer immunotherapy. In conclusion, we showed that a stoma alters the taxonomic and functional profiles in feces and may be a confounding factor in fecal microbiota analysis.
AB - Colorectal cancer (CRC) is one of the most common malignant diseases. Generally, stoma construction is performed following surgery for the resection of the primary tumor in patients with CRC. The association of CRC with the gut microbiota has been widely reported, and the gut microbiota is known to play an important role in the carcinogenesis, progression, and treatment of CRC. In this study, we compared the microbiota of patients with CRC between with and without a stoma using fecal metagenomic sequencing data from SCRUM-Japan MONSTAR-SCREEN, a joint industry-academia cancer research project in Japan. We found that the composition of anaerobes was reduced in patients with a stoma. In particular, the abundance of Alistipes, Akkermansia, Intestinimonas, and methane-producing archaea decreased. We also compared gene function (e.g., KEGG Orthology and KEGG pathway) and found that gene function for methane and short-chain fatty acids (SCFAs) production was underrepresented in patients with a stoma. Furthermore, a stoma decreased Shannon diversity based on taxonomic composition but increased that of the KEGG pathway. These results suggest that the feces of patients with a stoma have a reduced abundance of favorable microbes for cancer immunotherapy. In conclusion, we showed that a stoma alters the taxonomic and functional profiles in feces and may be a confounding factor in fecal microbiota analysis.
UR - http://www.scopus.com/inward/record.url?scp=85138933793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138933793&partnerID=8YFLogxK
U2 - 10.3389/fcimb.2022.925444
DO - 10.3389/fcimb.2022.925444
M3 - Article
C2 - 36189350
AN - SCOPUS:85138933793
VL - 12
JO - Frontiers in cellular and infection microbiology
JF - Frontiers in cellular and infection microbiology
SN - 2235-2988
M1 - 925444
ER -
